Immunological Effects of Interleukin-2 Therapy in Human Immunodeficiency Virus-Positive Subjects

DOI: 10.1128/CDLI.8.4.671-677.2001

Article Figures & Data

Table 1.

Therapeutic and immunological characteristics of relevant clinical trials including IL-2 for the treatment of HIV-positive patients

Investigators (reference)	Baseline CD4 count (no. of cells/mm³)	Treatment	CD4 increase [no. of cells/mm³ (%)] after:
Investigators (reference)	Baseline CD4 count (no. of cells/mm³)	Treatment	ART^a	IL-2 treatment
Simonelli et al. (58)	200–500	RTIs	+60	+256
Davey et al. (13)	>200	RTIs	ND	>200 (44), 0–200 (33)
Emery et al. (19)	100–500	RTIs	+153	+368
Levy et al. (36)	250–550	RTIs	+55	+564
Davey et al. (14)	200–500	HAART	+64	+384
Ruxrungtham et al. (55)	≥350	HAART	+42	+252
Abrams et al.^c	≥300	HAART	+22	+276

↵a ART, antiretroviral therapy.
b ND, not determined.
↵c Addendum Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. L11, p. 24, 2000.

Table 2.

Relevant results of clinical trials investigating immunological functions in IL-2 treated, HIV-positive patients^a

↵a Symbols and abbreviations: =, not modified; ↑, increased; AICD, activation-dependent cellular death; TT, tetanus toxoid; SS, streptokinase-streptodornase; PPD, purified protein derivative; Chemok., chemokine; CTL, cytotoxic T lymphocyte.